<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03446495</url>
  </required_header>
  <id_info>
    <org_study_id>R279741OVC4001</org_study_id>
    <nct_id>NCT03446495</nct_id>
  </id_info>
  <brief_title>An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer</brief_title>
  <acronym>Renaissance</acronym>
  <official_title>A Non-interventional, Multicenter Study of the Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suriya Yessentayeva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scientific Medical Society, Kazakhstan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Non-interventional, Multicenter study evaluating the efficacy and safety of the
      combination of pegylated liposomal doxorubicin and trabectedin in routine practice in
      patients with recurrent partial-platinum sensitive ovarian cancer, which is held in
      Kazakhstan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">May 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Patient will be followed during 37 weeks</time_frame>
    <description>ORR will be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST V 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Patient will be followed during 37 weeks</time_frame>
    <description>PFS is defined as the time from the 1st treatment cycle until objective tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety according to CTCAE v4.0</measure>
    <time_frame>Patient will be followed during 37 weeks</time_frame>
    <description>To assess patient safety and the tolerance of trabectedin + PLD</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Trabectedin + PLD</arm_group_label>
    <description>Trabectedin + PLD according to SmPC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin + PLD</intervention_name>
    <description>Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.</description>
    <arm_group_label>Trabectedin + PLD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsed ovarian cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;18

          -  Histologically proven epithelial ovarian cancer

          -  ECOG 0-1

          -  Partially platinum sensitive relapsed ovarian cancer: platinum-free interval 6 -12
             months

          -  With 1-2 or more cycles on trabectedin treatment at the recommended dose of 1.1mg/m2
             q3w 3hr infusion in combination of PLD at 30mg/ml with appropriate pre-medication

          -  Prior treatment with 1 or more chemotherapy regimen

        Exclusion Criteria:

          -  Platinum resistant disease: PFI &lt; 6 months (progression within six months after
             first-line platinum-based chemotherapy)

          -  Unwilling or unable to have a central venous catheter

          -  Patients with hepatic impairment (Patients with elevated bilirubin)

          -  Patients with renal impairment (Patients with serum creatinine &gt;1.5 mg/dL)

          -  Patients with hematologic impairment (baseline neutrophil counts of less than 1,500
             cells/mm3 and platelets count of less than 100,000 cells/mm3)

          -  Patients with serious impaired cardiac function (patients with cardiac disease and
             with reduction of the QRS complex)

          -  AIDS-related Kaposi's sarcoma

          -  Lactation or pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suriya Yessentaeva, PhD</last_name>
    <phone>+77077942910</phone>
    <email>surya_esentay@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Almaty oncological center</name>
      <address>
        <city>Almaty</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rinat Baituganov, PhD</last_name>
      <phone>+7 (727) 382 61 60</phone>
      <email>almaty.onco@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Rinat Baituganov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Almaty regional oncological dispensary</name>
      <address>
        <city>Almaty</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayakhat Olzhaev, PhD</last_name>
      <phone>+77273993881</phone>
      <email>arod_priem@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Sayakhat Olzhaev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazakh institute of oncology and radiology</name>
      <address>
        <city>Almaty</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dilara Kaidarova, Academician</last_name>
      <phone>+ 7 727 292 00 61</phone>
      <email>admin@ncc.org.kz</email>
    </contact>
    <investigator>
      <last_name>Dilara Kaidarova, academician</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kazakh institute of oncology and radiology</name>
      <address>
        <city>Almaty</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oxana Shatkovskaya, PhD</last_name>
      <phone>+77014147124</phone>
      <email>1972arty@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Oxana Shatkovskaya, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astana Oncology Center</name>
      <address>
        <city>Astana</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mukhtar Tuleutaev, PhD</last_name>
      <phone>+77172560073</phone>
    </contact>
    <investigator>
      <last_name>Mukhtar Tuleutaev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyzylorda regional Oncological center</name>
      <address>
        <city>Kyzylorda</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saken Sergaziyev, PhD</last_name>
      <phone>+77242235468</phone>
      <email>onkolog_kzo@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Saken Sergaziyev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Kazakhstan regional oncology dispensary</name>
      <address>
        <city>Oral</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esengeldy Rabaev, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Esengeldy Rabaev, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Kazakhstan Regional Oncology Center</name>
      <address>
        <city>Petropavlovsk</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ermek Abdrimov, PhD</last_name>
      <phone>+77152463201</phone>
      <email>sko.ood@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Ermek Abdrimov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Kazakhstan regional oncologic dispensary</name>
      <address>
        <city>Shymkent</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dauranbek Arybzhanov, PhD</last_name>
      <phone>+77252221904</phone>
      <email>onco-shm@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Dauranbek Arybzhanov, ЗрВ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Kazakhstan Regional Oncology Dispensary</name>
      <address>
        <city>Ust-Kamenogorsk</city>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulmira Sagidullina, PhD</last_name>
      <phone>+77112705976</phone>
      <email>vkood_poliklinika@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Gulmira Sagidullina, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Scientific Medical Society, Kazakhstan</investigator_affiliation>
    <investigator_full_name>Suriya Yessentayeva</investigator_full_name>
    <investigator_title>Chair</investigator_title>
  </responsible_party>
  <keyword>ovarian cancer, trabectedin, recurrent ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

